Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature / F. Croce, P. Vitiello, A. Dalla Pria, A. Riva, M. Galli, S. Antinori. - In: INTERNATIONAL JOURNAL OF STD & AIDS. - ISSN 0956-4624. - 21:11(2010), pp. 783-785. [10.1258/ijsa.2010.010246]
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
F. CrocePrimo
;P. VitielloSecondo
;A. DALLA PRIA;A. Riva;M. GalliPenultimo
;S. AntinoriUltimo
2010
Abstract
Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
